High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA

Prostate

Volumn 70, Issue 13, 2010, Pages 1413-1421

  Alt, Karen ^a,b   Wiehr, Stefan ^c   Ehrlichmann, Walter ^c   Reischl, Gerald ^c   Wolf, Philipp ^a   Pichler, Bernd J ^c   Elsässer Beile, Ursula ^a   Bühler, Patrick ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Monoclonal antibodies; PET; Prostate cancer; PSMA; Tumor localization

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID COPPER 64; CHELATING AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRACER; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CELL ADHESION; CONJUGATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG UPTAKE; IMAGING; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TUMOR XENOGRAFT; ANIMAL; DOSE RESPONSE; IMMUNOLOGY; PROSTATE; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GLUTAMATE CARBOXYPEPTIDASE II; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 77956620624     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21176     Document Type: Article

References (31)

1. Wu AM, Yazaki PJ, Tsai S, Nguyen K, Anderson AL, McCarthy DW, Welch MJ, Shively JE, Williams LE, Raubitschek AA, Wong JY, Toyokuni T, Phelps ME, Gambhir SS,. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA 2000; 97 (15): 8495 -8500.
2. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM,. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003; 44 (12): 1962 -1969.
3. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM,. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005; 65 (2): 622 -631.
4. Zimmermann K, Grunberg J, Honer M, Ametamey S, Schubiger PA, Novak-Hofer I,. Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: Selection of copper ligands and PET imaging. Nucl Med Biol 2003; 30 (4): 417 -427.
5. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM,. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005; 65 (13): 5907 -5916.
6. Schulke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC,. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA 2003; 100 (22): 12590 -12595.
7. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R,. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 2006; 25 (6): 1375 -1384.
8. Ghosh A, Heston WD,. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91 (3): 528 -539.
9. Elssser-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U,. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006; 66 (13): 1359 -1370.
10. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, Anderson CJ, Welch MJ,. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 1997; 24 (1): 35 -43.
11. Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, Welch MJ, Anderson CJ,. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med 2003; 44 (8): 1284 -1292.
12. Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, Wetterauer U, Elssser-Beile U,. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2010; 70 (5): 562 -569.
13. Liu J, Kopeckova P, Bühler P, Wolf P, Pan H, Bauer H, Elssser-Beile U, Kopecek J,. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm 2009; 6 (3): 959 -970.
14. Elssser-Beile U, Reischl G, Wiehr S, Bühler P, Wolf P, Alt K, Shively J, Judenhofer MS, Machulla HJ, Pichler BJ,. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009; 50 (4): 606 -611.
15. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, Thielscher A, Kneilling M, Lichy MP, Eichner M, Klingel K, Reischl G, Widmaier S, Rocken M, Nutt RE, Machulla HJ, Uludag K, Cherry SR, Claussen CD, Pichler BJ,. Simultaneous PET-MRI: A new approach for functional and morphological imaging. Nat Med 2008; 14 (4): 459 -465.
16. Wu AM, Senter PD,. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23 (9): 1137 -1146.
17. Vogel CA, Bischof-Delaloye A, Mach JP, Pelegrin A, Hardman N, Delaloye B, Buchegger F,. Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab )2 fragment in nude mice bearing different human colon cancer xenografts. Br J Cancer 1993; 68 (4): 684 -690.
18. Tsai SW, Li L, Williams LE, Anderson AL, Raubitschek AA, Shively JE,. Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments. Bioconjug Chem 2001; 12 (2): 264 -270.
19. Trejtnar F, Laznicek M,. Analysis of renal handling of radiopharmaceuticals. Q J Nucl Med 2002; 46 (3): 181 -194.
20. Forster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM,. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: Strategies for reduction of the renal dose. J Nucl Med 2006; 47 (1): 140 -149.
21. Akizawa H, Uehara T, Arano Y,. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev 2008; 60 (12): 1319 -1328.
22. Kahn D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, Weiner GJ, Bushnell D, Gulfo J,. Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994; 152 (5 Pt 1): 1490 -1495.
23. Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, Spirnak JP, Carlin B, Bellon EM, Rogers B,. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Clin Nucl Med 1996; 21 (10): 759 -767.
24. Haseman MK, Reed NL, Rosenthal SA,. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 1996; 21 (9): 704 -713.
25. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, Gambhir SS, Hoh CK,. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162 (4): 1322 -1328.
26. Troyer JK, Beckett ML, Wright GL Jr,. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997; 30 (4): 232 -242.
27. Elsasser-Beile U, Buhler P, Wolf P,. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009; 10 (2): 118 -125.
28. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA,. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60 (21): 6095 -6100.
29. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH,. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44 (4): 610 -617.
30. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH,. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. Prostate 2004; 58 (2): 145 -155.
31. Olson WC, Heston WD, Rajasekaran AK,. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007; 2 (3): 182 -190.